Of the 27 A-share listed biopharmaceutical companies that have released the third quarter forecasting reports, 24 have achieved good performance, accounting for 88.89%.
On the evening of October 14, the A-share listed company Andon Health (Chinese: 九安医疗, 002432) released the forecast for the third quarter report. The company expects that the performance will increase significantly from January to September 2022. The net profit attributable to shareholders of the company will be CNY 16 billion (USD 2.22 billion) to 16.3 billion, with a year-on-year increase of 31818.29% to 32416.76%. It is estimated that the basic earnings per share will be CNY 35.09 to 35.75.
The trading limit was reached on October 17, the next trading day after the announcement.
Andon Health’s business involves IVD (In Vitro Diagnostics), home-use medical supplies and equipment, and Internet-based medicine.
Andon Health indicates that the growth of the achievements was due to the strong demand for iHealth COVID-19 Antigen Rapid Test in the United States market and the continued rise of the exchange rate for the US dollar.
From the net profit growth rate perspective, five companies have exceeded 100%. Among them, Northeast Pharm (Chinese: 东北制药, 000597) and MGI Tech (Chinese: 华大智造, 688114) ranked second and third, respectively. Northeast Pharm expected its net profit increased by 351.02% to 449.07% in the first three quarters. MGI Tech expects its net profit in the first three quarters to grow by 311.80% to 340.08%. Followed by Wantai BioPharm (Chinese: 万泰生物, 603392) at fourth and Hybribio (Chinese: 凯普生物, 300639) at fifth.